2015 American Transplant Congress
Should Current IVIg Preparations Containing High Titers of Anti-HLA-I/-II IgG be Used for Lowering the Anti-HLA IgG in Sensitized Pre-Transplant Patients and Allograft Recipients?
HLA antibodies, Terasaki Foundation Laboratory, Los Angeles, CA.
Sera of non-alloimmunized individuals contain anti-HLA-I & -II IgG. Therefore it is reasonable expect HLA-I/-II reactivity of Intravenous Immunoglobulin (IVIg). However, the titers at which…2015 American Transplant Congress
Variants Associated With Tacrolimus Troughs in European American Kidney Transplant Recipients: A Genome Wide Association Study
Tacrolimus (tac) is dependent on CYP3A4/5 for metabolism. Variability in the metabolism is influenced by CYP3A5*3 alleles. This variant and clinical factors explain around 50%…2015 American Transplant Congress
Systemic and Local NK and Regulatory Cell Phenotypes and mTori-Induced Tumor-Specific Effector T-Cell Responses Are Key Players Favoring the Development of Squamous Cell Skin Carcinoma Among Kidney Transplant Patients
Renal transplant patients are at higher risk of developing squamous cell carcinoma (SCC). Immunosuppressive agents promote an imbalance between effector and regulatory tumor-specific immune responses,…2015 American Transplant Congress
Molecular Marker Strategies Supporting the Novartis US92 Study- A Discovery Study of Protein Biomarkers for Kidney Function (eGFR) and Acute Rejection in Serum from Renal Transplant Patients
Purpose. Protein biomarkers have the potential to allow for earlier and more specific diagnosis of kidney injury in kidney transplant patients than established clinical markers…2015 American Transplant Congress
Evaluation of Natural Killer Cell Activation by NK Cell-Specific Interferon-Gamma-Releasing Assay
Introduction: Although NK cell activity (NKA) has a variety of measuring markers including chromiun release assay and flowcytometry-based cytolysis, limitations such as radioactivity and lack…2015 American Transplant Congress
Biomarker Panel Profile for Identification of High-Risk Patients After Heart Transplantation
Background: The first year after cardiac transplantation is critical for transplant survival and long-term outcome. Identification of suitable biomarkers for detection of rejection processes is…2015 American Transplant Congress
Development and Validation of a Genotype Guided Tacrolimus Dosing Equation for African American (AA) Kidney Transplant Recipients
Tacrolimus (tac) has a strong exposure-response relationship with high inter-individual variability in troughs and dose. Tac dose requirements for AA patients are higher than Caucasians,…2015 American Transplant Congress
Non-Invasive Immune Monitoring Assay in Transplant Recipients
A reliable non-invasive assay of immune responsiveness would help to predict the development of chronic rejection, stable function or tolerance in transplant recipients. Our aim…2015 American Transplant Congress
Generation, Cryopreservation, Function and In Vivo Fate of Ex-Vivo Expanded Cynomolgus
Background:Foxp3+ regulatory T cells (Treg) function to promote immune tolerance and prevent immunopathogenesis. Preclinical studies have demonstrated that adoptive transfer of Treg prevents rejection of…2015 American Transplant Congress
Alemtuzumab Induction Is Protective Against Acute Rejection in Kidney Recipients With Subtherapeutic Tacrolimus Concentrations
Transplant Surgery, University of North Carolina Hospitals, Chapel Hill, NC.
Purpose: To determine the effect of attaining early therapeutic tacrolimus (TAC) trough concentrations on biopsy-proven acute rejection (BPAR) within 12 months post-transplantation in adult kidney…
American Transplant Congress abstracts